Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 07, 2016 6:23 AM ET

Biotechnology

Company Overview of Ardelyx, Inc.

Company Overview

Ardelyx, Inc. discovers, develops, and commercializes minimally-systemic small molecule therapeutics for the gastrointestinal (GI) tract to treat cardio-renal, GI, and metabolic diseases. Its lead product candidate is tenapanor, a small molecule NHE3 inhibitor, which has completed Phase 2b clinical trial for the treatment of patients with constipation-predominant irritable bowel syndrome and hyperphosphatemic patients with chronic kidney disease on dialysis, as well as Phase 2a clinical trial in patients with late-stage chronic kidney disease. The company’s discovery and lead development programs that are in research phase include RDX002 NaP2b inhibitor for hyperphosphatemia; RDX009 TGR5 ago...

34175 Ardenwood Boulevard

Suite 100

Fremont, CA 94555

United States

Founded in 2007

34 Employees

Phone:

510-745-1700

Fax:

510-745-0493

Key Executives for Ardelyx, Inc.

Chief Executive Officer, President and Director
Age: 50
Total Annual Compensation: $466.0K
Chief Financial Officer
Age: 47
Total Annual Compensation: $318.9K
Chief Scientific Officer and Executive Vice President
Age: 46
Total Annual Compensation: $132.1K
Compensation as of Fiscal Year 2014.

Ardelyx, Inc. Key Developments

Ardelyx, Inc. - Special Call

To discuss RDX022 clinical trial results

Ardelyx, Inc. Announces Positive Results of Open Label Clinical Study Evaluating the Pharmacodynamic (PD) Activity of RDX022 in Healthy Adult Volunteerrkalemia

Ardelyx, Inc. announced positive results of an open label clinical study evaluating the pharmacodynamic (PD) activity of RDX022 in healthy adult volunteers. The study demonstrated that RDX022, Ardelyx's proprietary potassium binder for the treatment of hyperkalemia, effectively binds potassium in the gastrointestinal tract supporting plans to proceed with a Phase 3 clinical program currently expected to begin in the second half of 2016. RDX022 was generally well-tolerated at all doses administered (up to 27.5 g/day) in the study. This open-labeled pharmacodynamic (PD) study of RDX022 consisted of a two-day treatment-free baseline period and a four-day treatment period. The study included four cohorts, and in each cohort, 12 subjects received RDX022 and three subjects received a similar dose of sodium polystyrene sulfonate (SPS) for a total of 60 subjects. RDX022 was administered at 4.6 g BID (9.2 g/day), 6.9 g BID (13.8 g/day), 4.6 g TID (13.8 g/day) and 9.2 g TID (27.5 g/day), and resulted in a mean increase of fecal potassium from baseline of 888 mg/day, 1,791 mg/day, 1,408 mg/day, and 1,670 mg/day, respectively. RDX022 was generally well-tolerated at all doses and demonstrated comparable results to those observed with sodium polystyrene sulfonate (SPS). Other fecal electrolytes were monitored during the study and no unexpected changes were observed; in particular, fecal magnesium remained unchanged from baseline. The results of the study will be presented in a future scientific format.

Ardelyx, Inc. Appoints Paul Korner as Executive Vice President and Chief Medical Officer

Ardelyx, Inc. announced that Paul Korner, MD, MBA, joined the company in a newly created position as Executive Vice President and Chief Medical Officer. Dr. Korner joins Ardelyx with 17-years of pharmaceutical industry experience, having served in various leadership positions of increased responsibility with several global companies. Over the past seven years, he served as President, Ferring International Pharmascience Center U.S. Inc. (FIPCUS) & Senior Vice President, U.S. Development for Ferring Pharmaceuticals where he built and led Ferring's U.S. clinical development subsidiary responsible for gastroenterology, reproductive health, orthopedics and urology therapeutic areas and was a member of senior global R & D management.

Similar Private Companies By Industry

Company Name Region
Applied Molecular Transport, LLC United States
Verdeca LLC United States
GeneExcel, Inc. United States
Edison Agrosciences, Inc. United States
StemSource Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
June 2, 2015
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Ardelyx, Inc., please visit www.ardelyx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.